- Home
- GBR vs SILO Comparison
GBR vs SILO Comparison
Compare GBR & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBR | SILO |
|---|---|---|
| Founded | 1978 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Apparel |
| Sector | Energy | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GBR | SILO |
|---|---|---|
| Price | $0.85 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 51.1K | ★ 159.9K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $153,000.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $0.67 | $0.33 |
| 52 Week High | $1.78 | $2.16 |
Technical Indicators
Market Signals| Indicator | GBR | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 57.54 | N/A |
| Support Level | $0.80 | N/A |
| Resistance Level | $0.92 | N/A |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 64.42 | 0.00 |
Price Performance
Historical ComparisonAbout GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.